-transparent.png){kind=logo}
In a double blind, placebo-controlled study the effects of daily oral administration of 3-cyano-imipramine on the 3H-serotonin uptake capacity of platelets were investigated in healthy volunteers. The initial dose was 1 mg, rising to 3 mg daily for 7 days. A rapid and profound inhibition of 3H-serotonin uptake was observed in platelets isolated from the treated subjects. During repeated administration, uptake was reduced to less than 10% of pre-drug values. Five days after the final dose uptake had only partially recovered, to 53% of pre-drug values. A similar inhibition profile was observed when serum from the treated subjects was incubated with normal platelets and 3H-serotonin. The results establish 3-cyano-imipramine as a potent inhibitor of platelet serotonin uptake in humans.
T J Lenehan, and
M Kenny, and
L M Omer, and
R Lambe, and
I Brick, and
A Darragh
January 1988,
Psychopharmacology,
T J Lenehan, and
M Kenny, and
L M Omer, and
R Lambe, and
I Brick, and
A Darragh
December 1989,
Biological psychiatry,
T J Lenehan, and
M Kenny, and
L M Omer, and
R Lambe, and
I Brick, and
A Darragh
January 1989,
Journal of affective disorders,
T J Lenehan, and
M Kenny, and
L M Omer, and
R Lambe, and
I Brick, and
A Darragh
July 1991,
Acta psychiatrica Scandinavica,
T J Lenehan, and
M Kenny, and
L M Omer, and
R Lambe, and
I Brick, and
A Darragh
February 1985,
Life sciences,
T J Lenehan, and
M Kenny, and
L M Omer, and
R Lambe, and
I Brick, and
A Darragh
March 2012,
Clinical pharmacology and therapeutics,
T J Lenehan, and
M Kenny, and
L M Omer, and
R Lambe, and
I Brick, and
A Darragh
January 1985,
General pharmacology,
T J Lenehan, and
M Kenny, and
L M Omer, and
R Lambe, and
I Brick, and
A Darragh
January 1993,
Therapie,
T J Lenehan, and
M Kenny, and
L M Omer, and
R Lambe, and
I Brick, and
A Darragh
October 1988,
Journal of cardiovascular pharmacology,
T J Lenehan, and
M Kenny, and
L M Omer, and
R Lambe, and
I Brick, and
A Darragh
April 1985,
Life sciences,
